These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Omalizumab is effective in patients with chronic spontaneous urticaria plus multiple chronic inducible urticaria. Skander D; Allenova A; Maurer M; Kolkhir P Eur Ann Allergy Clin Immunol; 2021 Mar; 53(2):91-93. PubMed ID: 32496030 [No Abstract] [Full Text] [Related]
3. Chronic spontaneous urticaria treated with omalizumab: what differentiates early from late responders? Asero R Eur Ann Allergy Clin Immunol; 2021 Jan; 53(1):47-48. PubMed ID: 32378398 [No Abstract] [Full Text] [Related]
4. Omalizumab re-treatment rates in chronic spontaneous urticaria. Khan S; Sholtysek S Eur Ann Allergy Clin Immunol; 2020 May; 52(4):187-189. PubMed ID: 32378397 [No Abstract] [Full Text] [Related]
5. Plasma adenosine is linked to disease activity and response to treatment in patients with chronic spontaneous urticaria. Mao M; Liu H; Yan S; Yuan Y; Liu R; Wu Y; Peng C; Li J; Chen X Allergy; 2021 Feb; 76(2):571-573. PubMed ID: 32687639 [No Abstract] [Full Text] [Related]
6. Real world evidence on treatment of chronic spontaneous urticaria with omalizumab: Preliminary data. Corrao S; Prestigiacomo MA; Angileri RG; Natoli G; Argano C Dermatol Ther; 2020 Jul; 33(4):e13458. PubMed ID: 32319167 [No Abstract] [Full Text] [Related]
7. Safety of omalizumab treatment in patients with chronic spontaneous urticaria and COVID-19. Passante M; Napolitano M; Dastoli S; Bennardo L; Fabbrocini G; Nisticò SP; Patruno C Dermatol Ther; 2021 Nov; 34(6):e15111. PubMed ID: 34427028 [No Abstract] [Full Text] [Related]
8. Children with chronic spontaneous urticaria: Recurrence after remission and its predictors. Özyılmaz-Bozat G; Şahiner ÜM; Buyuktiryaki B; Uysal-Soyer Ö; Şekerel BE J Allergy Clin Immunol Pract; 2020 Feb; 8(2):796-798.e1. PubMed ID: 31425834 [No Abstract] [Full Text] [Related]
11. Efficacy of additional treatment for chronic spontaneous urticaria refractory to treatment - A single-center retrospective real-world study. Ohata M; Oda Y; Washio K; Fukunaga A; Nishigori C J Dermatol; 2022 Jan; 49(1):e7-e8. PubMed ID: 34632611 [No Abstract] [Full Text] [Related]
12. Chronic spontaneous urticaria in the United States: patient characteristics and treatment patterns. Pourali SP; Gutierrez Y; Kucharik AH; Rajkumar JR; Jones ME; Armstrong AW Int J Dermatol; 2022 Aug; 61(8):e308-e309. PubMed ID: 34370872 [No Abstract] [Full Text] [Related]
13. Validation of UAS7 among children with chronic spontaneous urticaria. Gabrielli S; Mulé P; Prosty C; Gooding G; Le M; Zhang L; Netchiporouk E; Baum S; Greenberger S; Ensina LF; Lovett A; Zhang X; Ben-Shoshan M J Allergy Clin Immunol Pract; 2022 Jul; 10(7):1927-1929.e1. PubMed ID: 35272072 [No Abstract] [Full Text] [Related]
14. Omalizumab in children and adolescents with chronic spontaneous urticaria: Case series and review of the literature. Passanisi S; Arasi S; Caminiti L; Crisafulli G; Salzano G; Pajno GB Dermatol Ther; 2020 Jul; 33(4):e13489. PubMed ID: 32358910 [TBL] [Abstract][Full Text] [Related]
15. It is never too late to treat chronic spontaneous urticaria with omalizumab: Real-life data from a multicenter observational study focusing on elderly patients. Martina E; Damiani G; Grieco T; Foti C; Pigatto PDM; Offidani A Dermatol Ther; 2021 Mar; 34(2):e14841. PubMed ID: 33527659 [TBL] [Abstract][Full Text] [Related]
16. An observational study on the efficacy of single injection of omalizumab in the treatment of chronic spontaneous urticaria. Lal Vijayalal S; Arora S; Dabas R; Janney MS; Jankal Basavarajappa S; Das NM Dermatol Ther; 2020 Nov; 33(6):e14397. PubMed ID: 33040395 [TBL] [Abstract][Full Text] [Related]
17. [HOW PERIPHERAL BASOPHILS IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA ARE CHANGED WITH OMALIZUMAB TREATMENT?]. Oda Y; Washio K; Mizuno M; Imamura S; Nishigori C; Fukunaga A Arerugi; 2021; 70(9):1196-1199. PubMed ID: 34759084 [No Abstract] [Full Text] [Related]
18. Effectiveness of as-needed antihistamines in chronic spontaneous urticaria patients under omalizumab treatment. Türk M; Yılmaz İ; Nazik Bahçecioğlu S; Can P; Ertaş R; Kartal D; Çınar SL; Kocatürk E Dermatol Ther; 2021 Jan; 34(1):e14543. PubMed ID: 33190334 [TBL] [Abstract][Full Text] [Related]
19. A very low number of circulating basophils is predictive of a poor response to omalizumab in chronic spontaneous urticaria. Rijavec M; Košnik M; Koren A; Kopač P; Šelb J; Vantur R; Kogovšek Ž; Bizjak M; Bajrović N; Zidarn M; Korošec P Allergy; 2021 Apr; 76(4):1254-1257. PubMed ID: 32876979 [No Abstract] [Full Text] [Related]
20. Pityriasis rosea during omalizumab treatment for chronic spontaneous urticaria. Vaccaro M; Marafioti I; Cannavò SP; Ciccarese G; Drago F Dermatol Ther; 2020 Nov; 33(6):e14356. PubMed ID: 33009684 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]